{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:26:51Z","timestamp":1794864411562,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021772","name":"Deanship of Scientific Research, University of Jordan","doi-asserted-by":"publisher","award":["2451"],"award-info":[{"award-number":["2451"]}],"id":[{"id":"10.13039\/501100021772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30452","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T11:53:48Z","timestamp":1714218828000},"page":"e30452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Diagnosing Parkinson\u2019s disease and monitoring its progression: Biomarkers from combined GC-TOF MS and LC-MS\/MS untargeted metabolomics"],"prefix":"10.1016","volume":"10","author":[{"given":"Lina A.","family":"Dahabiyeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-3311","authenticated-orcid":false,"given":"Refat M.","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4238-5304","authenticated-orcid":false,"given":"Jeremiah D.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Y.","family":"Abu-rish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.heliyon.2024.e30452_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30452_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30452_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30452_bib4","article-title":"Clinical features of Parkinson's disease: the Evolution of critical symptoms","volume":"9","author":"Varadi","year":"2020","journal-title":"Biology-Basel"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30452_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","article-title":"Prediagnostic presentations of Parkinson's disease in primary care: a case-control study","volume":"14","author":"Schrag","year":"2015","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30452_bib7","first-page":"504","article-title":"Parkinson's disease and its management: Part 1: disease Entity, risk factors, pathophysiology, clinical presentation, and diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"Pharmacy and therapeutics"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30452_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.neurol.2012.07.004","article-title":"When does Parkinson's disease begin? From prodromal disease to motor signs","volume":"168","author":"Meissner","year":"2012","journal-title":"Rev. Neurol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30452_bib9","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson's disease","volume":"30","author":"Berg","year":"2015","journal-title":"Movement Disorders"},{"key":"10.1016\/j.heliyon.2024.e30452_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.20517\/2347-8659.2020.58","article-title":"A review on Parkinson's disease treatment","volume":"8","author":"Lee","year":"2021","journal-title":"Neuroimmunol. Neuroinflammation"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e30452_bib11","doi-asserted-by":"crossref","first-page":"16690","DOI":"10.18632\/aging.103992","article-title":"Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease","volume":"12","author":"Yakhine-Diop","year":"2020","journal-title":"Aging-Us"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30452_bib12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/mds.27173","article-title":"Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis","volume":"32","author":"Han","year":"2017","journal-title":"Movement Disorders"},{"key":"10.1016\/j.heliyon.2024.e30452_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-06767-y","article-title":"Decreased long-chain acylcarnitines from insufficient beta-oxidation as potential early diagnostic markers for Parkinson's disease","volume":"7","author":"Saiki","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","article-title":"Identification of novel biomarkers for Parkinson's disease by metabolomic technologies","volume":"87","author":"Hatano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e30452_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/1423-0127-16-63","article-title":"Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection","volume":"16","author":"Ahmed","year":"2009","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30452_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-021-00425-8","article-title":"Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry","volume":"16","author":"Shao","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JPD-140389","article-title":"Metabolite and Peptide levels in plasma and CSF Differentiating healthy controls from patients with newly diagnosed Parkinson's disease","volume":"4","author":"Trupp","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.heliyon.2024.e30452_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2015.03.051","article-title":"NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls","volume":"594","author":"Ohman","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.heliyon.2024.e30452_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00051","article-title":"Promising metabolite profiles in the plasma and CSF of early clinical Parkinson's disease","volume":"10","author":"Stoessel","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031879","article-title":"Cerebrospinal fluid metabolome in Parkinson's disease and multiple system atrophy","volume":"23","author":"Kwon","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30452_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/pr500807t","article-title":"LC MS-based urinary metabolite Signatures in idiopathic Parkinson's disease","volume":"14","author":"Luan","year":"2015","journal-title":"J. Proteome Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30452_bib22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.parkreldis.2015.09.009","article-title":"Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's disease","volume":"21","author":"Luan","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30452_bib23","first-page":"S11","article-title":"Parkinsonism: onset, progression, and mortality (Reprinted from Neurology","volume":"57","author":"Hoehn","year":"2001","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30452_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/metabo13090990","article-title":"Serum-based lipid panels for diagnosis of IdiopathicParkinson's disease","volume":"13","author":"Dahabiyeh","year":"2023","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30452_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/metabo9050101","article-title":"A comprehensive plasma metabolomics dataset for a cohort of Mouse knockouts within the international mouse phenotyping consortium","volume":"9","author":"Barupal","year":"2019","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30452_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.3393","article-title":"MS-DIAL: data-independent MS\/MS deconvolution for comprehensive metabolome analysis","volume":"12","author":"Tsugawa","year":"2015","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib27","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1021\/acs.analchem.8b04698","article-title":"Structure annotation of all mass spectra in untargeted metabolomics","volume":"91","author":"Blazenovic","year":"2019","journal-title":"Anal. Chem."},{"issue":"W1","key":"10.1016\/j.heliyon.2024.e30452_bib28","doi-asserted-by":"crossref","first-page":"W388","DOI":"10.1093\/nar\/gkab382","article-title":"MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights","volume":"49","author":"Pang","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30452_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nprot.2011.319","article-title":"Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst","volume":"6","author":"Xia","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.heliyon.2024.e30452_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15231-w","article-title":"Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets","volume":"7","author":"Barupal","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30452_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30452_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9090902","article-title":"Antioxidant and neuroprotective effects of caffeine against alzheimer's and Parkinson's disease: insight into the role of nrf-2 and A2AR signaling","volume":"9","author":"Ikram","year":"2020","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30452_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ana.1052","article-title":"Prospective study of caffeine consumption and risk of Parkinson's disease in men and women","volume":"50","author":"Ascherio","year":"2001","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30452_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.parkreldis.2011.02.016","article-title":"Intake of Japanese and Chinese teas reduces risk of Parkinson's disease","volume":"17","author":"Tanaka","year":"2011","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3233\/JPD-191882","article-title":"Associations of lower caffeine intake and plasma urate levels with idiopathic Parkinson?s disease in the harvard biomarkers study","volume":"10","author":"Bakshi","year":"2020","journal-title":"J. Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30452_bib36","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004888","article-title":"Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease","volume":"90","author":"Fujimaki","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30452_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201260","article-title":"Biomarker repurposing: therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease","volume":"13","author":"Ohmichi","year":"2018","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e30452_bib38","doi-asserted-by":"crossref","first-page":"E3428","DOI":"10.1212\/WNL.0000000000010863","article-title":"Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers A metabolomic study","volume":"95","author":"Crotty","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30452_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0301-0082(95)00014-M","article-title":"N-ACETYLASPARTATE in neuropsychiatric disorders","volume":"46","author":"Tsai","year":"1995","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1385\/NMM:3:2:95","article-title":"Brain damage results in down-regulation of N-acetylaspartate as a neuronal osmolyte","volume":"3","author":"Baslow","year":"2003","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.heliyon.2024.e30452_bib41","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"5221","article-title":"Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease","author":"Madhavarao","year":"2005"},{"key":"10.1016\/j.heliyon.2024.e30452_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.617308","article-title":"Brain metabolite, N-acetylaspartate is a potent protein aggregation inhibitor","volume":"15","author":"Warepam","year":"2021","journal-title":"Front. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2006.12.003","article-title":"N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology","volume":"81","author":"Moffett","year":"2007","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.parkreldis.2012.11.012","article-title":"Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment","volume":"19","author":"Nie","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ageing\/afr021","article-title":"Age-related changes of serum N-acetyl-aspartate in healthy controls","volume":"40","author":"Ruggieri","year":"2011","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clnu.2004.11.001","article-title":"Polyamines: metabolism and implications in human diseases","volume":"24","author":"Moinard","year":"2005","journal-title":"Clin. Nutr."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00726-004-0070-z","article-title":"Catabolism of polyamines","volume":"26","author":"Seiler","year":"2004","journal-title":"Amino Acids"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30452_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016055","article-title":"N8-Acetylspermidine: a polyamine biomarker in ischemic cardiomyopathy with reduced ejection fraction","volume":"9","author":"Nayak","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30452_bib49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/neu.2009.1097","article-title":"Polyamine catabolism is enhanced after traumatic brain injury","volume":"27","author":"Zahedi","year":"2010","journal-title":"J. Neurotrauma"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ana.25516","article-title":"A metabolic profile of polyamines in Parkinson disease: a promising biomarker","volume":"86","author":"Saiki","year":"2019","journal-title":"Ann. Neurol."},{"issue":"19\u201320","key":"10.1016\/j.heliyon.2024.e30452_bib51","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.cca.2010.05.034","article-title":"Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy","volume":"411","author":"Paik","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30452_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077629","article-title":"Serum metabolomics of slow vs. Rapid motor progression Parkinson's disease: a pilot study","volume":"8","author":"Roede","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30452_bib53","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tips.2018.02.011","article-title":"Lysophosphatidylinositols, from cell membrane constituents to GPR55 ligands","volume":"39","author":"Alhouayek","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e30452_bib54","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s00018-006-6155-y","article-title":"New developments in the biological functions of lysophospholipids","volume":"63","author":"Birgbauer","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.heliyon.2024.e30452_bib55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","article-title":"GPR55: a therapeutic target for Parkinson's disease?","volume":"125","author":"Celorrio","year":"2017","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30452_bib56","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00004647-200207000-00007","article-title":"A potent protective role of lysophospholipids against global cerebral ischemia and glutamate excitotoxicity in neuronal cultures","volume":"22","author":"Blondeau","year":"2002","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e30452_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24132377","article-title":"New insights into the cystine-sulfite reaction","volume":"24","author":"Zecchini","year":"2019","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30452_bib58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bph.14464","article-title":"Homeostatic impact of sulfite and hydrogen sulfide on cysteine catabolism","volume":"176","author":"Kohl","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30452_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005072-197503000-00005","article-title":"CYSTEINE-S-SULFATE - brain damaging metabolite in sulfite oxidase deficiency","volume":"34","author":"Olney","year":"1975","journal-title":"JNEN (J. Neuropathol. Exp. Neurol.)"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30452_bib60","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1172\/JCI89885","article-title":"S-sulfocysteine\/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency","volume":"127","author":"Kumar","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e30452_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184391","article-title":"Roles of glutamate receptors in Parkinson's disease","volume":"20","author":"Zhang","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024064831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024064831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:40:53Z","timestamp":1778884853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024064831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024064831"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30452","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosing Parkinson\u2019s disease and monitoring its progression: Biomarkers from combined GC-TOF MS and LC-MS\/MS untargeted metabolomics","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30452"}}